HER2零表达与低表达乳腺癌的临床特征和新辅助治疗效果分析OA

Objective To explore the differences in clinical characteristics and neoadjuvant treatment outcomes between patients with human epidermal growth factor receptor 2(HER2)zero-expression(HER2-0)and HER2-low expression breast cancer.Methods Cli-nical data from 303 patients with HER2-0 and HER2-low breast cancer treated at the Department of Breast Surgery,the First Hospital of China Medical University,were collected from January 2016 to December 2020.The primary study endpoint was breast pathological complete response(bpCR).The t and χ2 test were used to compare the differences in clinical indicators between HER2-0 and HER2-low breast cancer patients.Univariate and multivariate logistic regression analyses were performed,combined with inverse probability of treat-ment weighting(IPTW)based on propensity scores,to compare differences in neoadjuvant therapy efficacy between patients with HER2-0 and HER2-low breast cancer and among patients with different hormone receptor(HR)expression statuses.Results No statistically significant differences were observed between HER2-0 and HER2-low patients in terms of age at diagnosis,menopausal status,reproduc-tive history,supraclavicular lymph node involvement,pectoral axillary lymph node involvement,preoperative clinical tumor(T)and node(N)stages;tumor,node,and metastasis(TNM)stage;and surgical approach(all P>0.05).No statistically significant differences in bpCR after neoadjuvant therapy were observed between HER2-low and HER2-0 patients(P>0.05).Among HR-negative patients,HER2-low patients showed significantly better bpCR after neoadjuvant therapy compared with HER2-0 patients(P<0.05).However,among HR-positive patients,no statistically significant differences in bpCR were observed between HER2-low and HER2-0 patients(P>0.05).Conclusion No significant differences in clinical characteristics were observed between HER2-0 and HER2-low breast cancer patients.The neoadjuvant treatment effect of HER2 low-expression patients is significantly better than that of HER2-0 patients among HR-negative patients.Therefore,HER2-low breast cancer with different HR expression levels may represent a distinct subtype that warrants further study.